Recombinant Human TNFRSF8 protein ,C- His Tag

Recombinant Human TNFRSF8 protein ,C- His Tag

>90% as determined by SDS-PAGE

Please contact with the lab for this information.

A DNA sequence encoding the human TNFRSF8(Met1-Lys379) was fused with the C-terminal His Tag

P28908

Mammalian cells

Homo sapiens (Human)

41.8kDa

Supplied as solution form in PBS or lyophilized from PBS .

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.

Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.

Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

TNFRSF8,CD30,D1S166E,Ki-1

Bartlett, Herrera, Domingo-Domenech, Mehta, Forero-Torres, Garcia-Sanz, Armand, Devata, Rodriguez Izquierdo, Lossos, Reeder, Sher, Chen, Schwarz, Alland, Strassz, Prier, Choe-Juliak, Ansell (2020) A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma Blood ()

For research use only .

In relapsed/refractory Hodgkin lymphoma (R/R HL), immunotherapies such as the PD-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy and are playing an increasingly prominent role in treatment. The CD30/CD16A bispecific antibody AFM13 is an innate immune cell engager, a first-in-class, tetravalent antibody, designed to create a bridge between CD30 on HL cells and the CD16A receptor on NK cells and macrophages, to induce tumor cell killing. Early studies of AFM13 have demonstrated signs of efficacy as monotherapy for patients with R/R HL and the combination of AFM13 with pembrolizumab represents a rational new treatment modality. Here, we describe a Phase 1b, dose-escalation study to assess the safety and preliminary efficacy of AFM13 in combination with pembrolizumab in patients with R/R HL. The primary objective was estimating the MTD; the secondary objectives were to assess safety, tolerability, anti-tumor efficacy, pharmacokinetics, and pharmacodynamics. In this heavily pre-treated patient population, the combination of AFM13 and pembrolizumab was generally well tolerated, with similar safety profiles compared to the known profiles of each agent alone. AFM13 plus pembrolizumab demonstrated objective response rates of 88% at the highest treatment dose, with an 83% ORR for the overall population. Pharmacokinetic assessment of AFM13 in the combination treatment revealed a half-life of up to 20.6 hours. This proof-of-concept study holds promise as a novel immunotherapy combination worthy of further investigation. This Phase 1b study was registered at www.clinicaltrials.gov as NCT02665650.

1搜索商品：关键字搜索；分类导航搜索；产品联系：手机/微信同号：15972188750，座机：027-65279366（推荐 ！）

2产品选购：确定好产品信息与规格，向产品客服询问底价

3提交订单：向客服提交收货人信息，选择送货方式，支付方式，发票信息

4产品发货：发票随产品一起发送，耐心等待收货即可

质量保证：

所售产品均经过严格的质量检验，确保所供产品的技术指标与生产厂家的目录、说明书、质检报告上的描述一致，请放心选购。

质量与免责说明：

买方验收产品时，如发现产品短缺、不匹配、包装破损等情况，请保持产品原包装状态，并在收货七个工作日内，以书面方式向我司提出异议。逾期未提出异议视为合格。

买方保管产品时，应按照产品标签、说明书所示保管条件保存，如系保管不当导致产品质量问题，恕不受理。

买方使用产品时。如发现产品质量问题，应在使用初期提出，而非在使用完或快使用完时提出，以备我司回收产品，确认产品质量。如确属质量问题，我司负责调换或退货。发生索赔事宜，我司将在产品价格额度范围内酌情赔偿，恕不受理超出产品本身价值之部分。自收货之日起，超过三个月未反映产品问题，恕不退换。

我司所提供的产品仅限于专业人士的科学研究使用，不得用于临床诊断或者治疗，若有单位或者个人擅自改变我司产品用途，我司不承担任何责任。